

Contains Nonbinding Recommendations

Draft – Not for Implementation

Draft Guidance on Crotamiton

October 2022

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Crotamiton

Dosage Form; Route: Cream; topical

Recommended Studies: Characterization tests

Acceptable comparative physicochemical and structural (Q3) characterization of the test product and reference standard should establish that they are the same dosage form, with identical strength. Refer to the most recent version of the FDA guidance for industry on *Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs*^a for additional information regarding appropriate comparative Q3 characterization tests.

Revision History: Recommended October 2016; Revised October 2022

Unique Agency Identifier: PSG_006927

^aFor the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>.